The abstract is read at the publisher; the summary is JClub's.
Personalized ctDNA profiling in 106 patients with high-risk localized soft tissue sarcoma detected baseline ctDNA in 85% and tracked perioperative changes linked to survival.
- Why it matters: Soft tissue sarcomas are rare, heterogeneous, and often have low mutational burden, making ctDNA detection and monitoring technically difficult. Prognostic and response tracking across radiotherapy and pembrolizumab treatment is therefore a key unmet need.
- What they did: In SU2C-SARC032, 313 plasma samples were analyzed pretreatment, after radiotherapy/presurgery, and postsurgery using tumor-informed assays tracking a median of 46 somatic mutations per patient. ctDNA levels were tested for associations with disease-free and overall survival using univariable and multivariable models adjusted for clinical risk factors.
- The result: Baseline ctDNA levels correlated with tumor size, grade 3 disease, and hypoxia and cell-cycle gene expression, and were strongly associated with disease-free and overall survival. Pembrolizumab-treated patients showed a greater ctDNA decrease after neoadjuvant therapy, and post-surgery detection of multiple tumor clones by ctDNA predicted inferior outcomes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.